Cover Image
市場調查報告書

內臟痛覺:開發中產品分析

Visceral Pain - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 283207
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
內臟痛覺:開發中產品分析 Visceral Pain - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 56 Pages
簡介

所謂內臟痛覺是指內臟發生的傷害性疼痛之一。主要症狀有微微的疼痛感、絞痛、擴大般的痛覺等。主要治療藥有止痛藥(麻醉·NSAID(非甾體抗炎藥物)及其它)和修飾藥(三環系抗憂鬱劑·抗痙攣藥及其它)等。

本報告提供全球各國治療內臟痛覺所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

內臟痛覺概要

治療藥的開發

  • 內臟痛覺開發中產品:概要
  • 內臟痛覺開發中產品:比較分析

各企業開發中的內臟痛覺治療藥

各大學/研究機關研究中的內臟痛覺治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

內臟痛覺治療藥:開發中的產品一覽(各企業)

內臟痛覺治療藥:研究中的產品一覽(各大學/研究機關)

內臟痛覺治療藥的開發企業

  • Addex Therapeutics Ltd
  • Astellas Pharma Inc.
  • Chromocell Corporation
  • GIcare Pharma Inc
  • Grunenthal GmbH
  • Medestea Research & Production S.p.A.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.

內臟痛覺:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

內臟痛覺治療藥:暫停中的計劃

內臟痛覺治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9062IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H1 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed and Preclinical stages are 1, 1 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Visceral Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Visceral Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Visceral Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Visceral Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Visceral Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Visceral Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Visceral Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Visceral Pain - Overview
  • Visceral Pain - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Visceral Pain - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Visceral Pain - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Anavex Life Sciences Corp
  • Astellas Pharma Inc
  • BELLUS Health Inc
  • Chromocell Corp
  • Eli Lilly and Company
  • GIcare Pharma Inc
  • Grunenthal GmbH
  • Medestea Research & Production SpA
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc
  • Visceral Pain - Drug Profiles
  • ADX-71441 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADX-71743 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANAVEX-1066 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ASP-7663 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLU-5937 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-8464 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GIC-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HS-665 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NeuP-12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NXN-677 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piromelatine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-656570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SBFI-26 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • URB-937 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WITH-1101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Visceral Pain - Dormant Projects
  • Visceral Pain - Discontinued Products
  • Visceral Pain - Product Development Milestones
  • Featured News & Press Releases
  • Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Visceral Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Visceral Pain - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Visceral Pain - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Visceral Pain - Pipeline by Astellas Pharma Inc, H1 2017
  • Visceral Pain - Pipeline by BELLUS Health Inc, H1 2017
  • Visceral Pain - Pipeline by Chromocell Corp, H1 2017
  • Visceral Pain - Pipeline by Eli Lilly and Company, H1 2017
  • Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2017
  • Visceral Pain - Pipeline by Grunenthal GmbH, H1 2017
  • Visceral Pain - Pipeline by Medestea Research & Production SpA, H1 2017
  • Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
  • Visceral Pain - Pipeline by Pfizer Inc, H1 2017
  • Visceral Pain - Dormant Projects, H1 2017
  • Visceral Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Visceral Pain - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Visceral Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top